A Phase 2 interventional study of Tradipitant and Placebo in Functional Dyspepsia, sponsored by Xiao Jing (Iris) Wang. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by Xiao Jing (Iris) Wang · Phase 2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Dyspepsia with a site in United States — 14 open to participants now, 18 under way, 1 of them phase 3. Dyspepsia · United States.
Among the 77 studies in Dyspepsia with a site in United States, this one is the 28th largest by planned enrollment of the 67 interventional ones that give a count, is one of 4 that started in 2023, is one of 8 in phase 2, reaches primary completion later than 5 of the 17 other live ones, and was the 62nd registered.
373 studies on the registry are indexed under Dyspepsia; 67 are open to participants now.
Browse Dyspepsia studies →14 of the 77 studies in Dyspepsia with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18+
Spaulding Rehabilitation Hospital · Sites in United States
Ages 18–65
Hospital Universitari Vall d'Hebron Research Institute · Sites in United States, Canada, France and 4 more countries
Ages 18–80 · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 46 Dyspepsia studies recruiting now, 16 (35%) set no upper age limit and 23 (50%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 14 · Phase 3 13 · Phase 4 2
First in 1999; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 88 across 303 interventional studies indexed under Dyspepsia.
Median enrollment 50 across the 67 interventional studies, 41 across the 10 observational. Of the 52 that completed or were terminated, 14 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 77 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Xiao Jing (Iris) Wang as lead sponsor.
Xiao Jing (Iris) Wang has 1 study filed under Dyspepsia — fewer than ten, so there is no comparison to draw.
7 of the studies in Dyspepsia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01696734Phase 3M.D. Anderson Cancer CenterDomperidone in Treating Patients With Gastrointestinal Disorders | 2027-10-31 |
| NCT05836597Mayo ClinicFunctional Dyspepsia Treatment Using Virtual Reality | 2026-12 |
| NCT06941545Mayo ClinicHigh Resolution Gastric Mapping and Gastroduodenal Manometry | 2026-12-31 |
| NCT05653310Xiao Jing (Iris) WangTradipitant for Functional Dyspepsia | 2027-03 |
| NCT06369753Hospital Universitari Vall d'Hebron Research InstituteVisible Abdominal Distension | 2027-04 |
Add all 7 to your calendar (.ics) → With an account.
Among the 77 studies in Dyspepsia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the effects of tradipitant relative to placebo on gastric motor functions, satiation, and postprandial symptoms in patients with functional dyspepsia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral Capsule
Drug: Tradipitant
Oral Capsule
Drug: Placebo
Tradipitant Capsule
Placebo Capsule
Accommodation gastric volumes measured by single photon emission computed tomography (SPECT)
Time frame: 4 Weeks
Plan to share: No
Started Feb 2023 (actual). Primary completion is estimated for Mar 2027, 49 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tradipitant